Allogene Therapeutics Inc (NASDAQ:ALLO) has a beta value of 0.83 and has seen 3.16 million shares traded in the last trading session. The company, currently valued at $667.84M, closed the last trade at $3.00 per share which meant it gained $0.28 on the day or 10.29% during that session. The ALLO stock price is -92.67% off its 52-week high price of $5.78 and 33.0% above the 52-week low of $2.01. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.33 million shares traded. The 3-month trading volume is 1.90 million shares.
The consensus among analysts is that Allogene Therapeutics Inc (ALLO) is Buy stock at the moment, with a recommendation rating of 1.53. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 6 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.33.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Allogene Therapeutics Inc (NASDAQ:ALLO) trade information
Sporting 10.29% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ALLO stock price touched $3.00 or saw a rise of 0.99%. Year-to-date, Allogene Therapeutics Inc shares have moved -6.54%, while the 5-day performance has seen it change 11.94%. Over the past 30 days, the shares of Allogene Therapeutics Inc (NASDAQ:ALLO) have changed 11.11%. Short interest in the company has seen 39.32 million shares shorted with days to cover at 19.93.
Wall Street analysts have a consensus price target for the stock at $33.5, which means that the shares’ value could jump 91.04% from current levels. The projected low price target is $7.0 while the price target rests at a high of $55.0. In that case, then, we find that the current price level is -1733.33% off the targeted high while a plunge would see the stock gain -133.33% from current levels.
Allogene Therapeutics Inc (ALLO) estimates and forecasts
Figures show that Allogene Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -0.33% over the past 6 months, with this year growth rate of 29.85%, compared to 17.50% for the industry. Revenue growth from the last financial year stood is estimated to be -36.80%.
14 analysts offering their estimates for the company have set an average revenue estimate of 10k for the current quarter. 14 have an estimated revenue figure of 10k for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 22.18% over the past 5 years. Earnings growth for 2024 is a modest 33.75% while over the next 5 years, the company’s earnings are expected to increase by 1.00%.
ALLO Dividends
Allogene Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Allogene Therapeutics Inc (NASDAQ:ALLO)’s Major holders
Insiders own 17.48% of the company shares, while shares held by institutions stand at 83.71% with a share float percentage of 101.45%. Investors are also buoyed by the number of investors in a company, with Allogene Therapeutics Inc having a total of 240.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 31.26 million shares worth more than $72.83 million. As of 2024-06-30, FMR LLC held 18.4816% of shares outstanding.
The other major institutional holder is TPG GP A, LLC, with the holding of over 18.72 million shares as of 2024-06-30. The firm’s total holdings are worth over $43.61 million and represent 11.0663% of shares outstanding.
